Retatrutide (RETA): Phase 3 TRIUMPH-4 Trial Results & Research Overview

Overview In December 2025, Eli Lilly announced the first successful Phase 3 results for GLP-3 RT (LY3437943) — a first-in-class triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. The TRIUMPH-4 trial represents a landmark moment in obesity and metabolic disease research, delivering weight loss figures that surpass any previously approved pharmacological intervention. This article summarises the key findings from TRIUMPH-4, contextualises them within the b

← Back to all articles

Peptidex — Research Grade Compounds UK. All products are for laboratory and scientific research use only. Not for human consumption.